Sign In
Buy STOK
$26.95
+0.440 (+1.66%)
At Close: Nov 17, 2025
BEDFORD, Mass., & CAMBRIDGE, Mass.--(BUSINESS WIRE)--Stoke Therapeutics, Inc. (Nasdaq: STOK), a biotechnology company dedicated to restoring protein expression by harnessing the body's potential with
Aviva PLC Takes $499,000 Position in Stoke Therapeutics, Inc. $STOK
04:01am, Friday, 14'th Nov 2025
Aviva PLC bought a new position in Stoke Therapeutics, Inc. (NASDAQ: STOK) during the undefined quarter, according to its most recent disclosure with the Securities and Exchange Commission (SEC). The
All You Need to Know About Stoke Therapeutics (STOK) Rating Upgrade to Buy
01:01pm, Wednesday, 05'th Nov 2025
Stoke Therapeutics (STOK) might move higher on growing optimism about its earnings prospects, which is reflected by its upgrade to a Zacks Rank #2 (Buy).
Stoke Therapeutics, Inc. (STOK) Reports Q3 Loss, Beats Revenue Estimates
07:01pm, Tuesday, 04'th Nov 2025
Stoke Therapeutics, Inc. (STOK) came out with a quarterly loss of $0.65 per share versus the Zacks Consensus Estimate of a loss of $0.54. This compares to a loss of $0.47 per share a year ago.
Stoke Therapeutics Reports Third Quarter 2025 Financial Results and Provides Business Updates
04:01pm, Tuesday, 04'th Nov 2025
BEDFORD, Mass.--(BUSINESS WIRE)--Stoke Therapeutics, Inc. (Nasdaq: STOK) is a biotechnology company dedicated to restoring protein expression by harnessing the body's potential with RNA medicine and h
Stoke Therapeutics (STOK) Projected to Post Earnings on Tuesday
03:30am, Sunday, 02'nd Nov 2025
Stoke Therapeutics (NASDAQ: STOK - Get Free Report) is anticipated to post its Q3 2025 results before the market opens on Tuesday, November 4th. Analysts expect Stoke Therapeutics to post earnings of
Stoke Therapeutics to Host Webcast and Conference Call to Discuss Third Quarter 2025 Business and Financial Updates
04:30pm, Thursday, 30'th Oct 2025
BEDFORD, Mass.--(BUSINESS WIRE)--Stoke Therapeutics, Inc. (Nasdaq: STOK) is a biotechnology company dedicated to restoring protein expression by harnessing the body's potential with RNA medicine and h
Stoke Therapeutics, Inc. $STOK Shares Bought by KLP Kapitalforvaltning AS
03:02am, Wednesday, 22'nd Oct 2025
KLP Kapitalforvaltning AS increased its stake in shares of Stoke Therapeutics, Inc. (NASDAQ: STOK) by 131.6% in the undefined quarter, according to its most recent 13F filing with the Securities and E
Stoke Therapeutics Presents Two-Year Natural History Data from Patients with Autosomal Dominant Optic Atrophy (ADOA)
07:30am, Monday, 20'th Oct 2025
BEDFORD, Mass.--(BUSINESS WIRE)--Stoke Therapeutics, Inc. (Nasdaq: STOK), a biotechnology company dedicated to restoring protein expression by harnessing the body's potential with RNA medicines, today
Stoke Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(C)(4)
04:30pm, Thursday, 16'th Oct 2025
BEDFORD, Mass.--(BUSINESS WIRE)--Stoke Therapeutics, Inc. (Nasdaq: STOK) is a biotechnology company dedicated to restoring protein expression by harnessing the body's potential with RNA medicine and h
BEDFORD, Mass., & CAMBRIDGE, Mass.--(BUSINESS WIRE)--Stoke Therapeutics, Inc. (Nasdaq: STOK), a biotechnology company dedicated to restoring protein expression by harnessing the body's potential with
Stoke Therapeutics (STOK) Surges 11.7%: Is This an Indication of Further Gains?
10:25am, Thursday, 09'th Oct 2025
Stoke Therapeutics (STOK) was a big mover last session on higher-than-average trading volume. The latest trend in earnings estimate revisions might not help the stock continue moving higher in the nea
Stoke Therapeutics Appoints Ian F. Smith as Chief Executive Officer
07:30am, Monday, 06'th Oct 2025
BEDFORD, Mass.--(BUSINESS WIRE)--Stoke Therapeutics, Inc. (Nasdaq: STOK), a biotechnology company dedicated to restoring protein expression by harnessing the body's potential with RNA medicine, today
Stoke Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(C)(4)
04:30pm, Tuesday, 16'th Sep 2025
BEDFORD, Mass.--(BUSINESS WIRE)--Stoke Therapeutics, Inc. (Nasdaq: STOK) is a biotechnology company dedicated to restoring protein expression by harnessing the body's potential with RNA medicine and h
BEDFORD, Mass. & CAMBRIDGE, Mass.--(BUSINESS WIRE)--Stoke Therapeutics, Inc. (Nasdaq: STOK), a biotechnology company dedicated to restoring protein expression by harnessing the body's potential with R
